Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03582124 · ClinicalTrials.gov registry record · Phase 1

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

A Phase 1 study of Stage IV Lung Cancer AJCC v8 and Lung Carcinoma, sponsored by Stanford University.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT03582124: Recruiting Phase 1 study of Stage IV Lung Cancer AJCC v8 and Lung Carcinoma, sponsored by Stanford University.

NCT03582124 is a Phase 1 study of Stage IV Lung Cancer AJCC v8 and Lung Carcinoma that is actively recruiting participants, run by Stanford University. The registered enrollment target is 30 participants, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03582124, a Phase 1 study of Stage IV Lung Cancer AJCC v8 and Lung Carcinoma, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

Conditions Studied

Stage IV Lung Cancer AJCC v8 Lung Carcinoma Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Metastatic Malignant Neoplasm in the Lung

Interventions

  • PROCEDURE Therapeutic Conventional Surgery
  • DRUG Panitumumab-IRDye800
  • PROCEDURE Near-Infrared Fluorescence Imaging
  • OTHER Pharmacokinetic Study

Study Locations (1)

California

  • Stanford University, School of Medicine - Palo Alto

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-07-19
Est. Completion 2026-09
Phase Phase 1

Sponsor

Stanford University

1,744 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03582124

The ClinicalTrials.gov registry entry for NCT03582124 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (69% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Stage IV Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Therapeutic Conventional Surgery is the first listed.

NCT03582124 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03582124 about?

NCT03582124 is a clinical study titled "Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery". This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camer...

What is the current status of trial NCT03582124?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-07-19. Estimated completion is 2026-09.

What conditions does trial NCT03582124 study?

This clinical trial studies the following conditions: Stage IV Lung Cancer AJCC v8, Lung Carcinoma, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Metastatic Malignant Neoplasm in the Lung.

What interventions are being tested in trial NCT03582124?

The interventions under investigation include: Therapeutic Conventional Surgery (PROCEDURE), Panitumumab-IRDye800 (DRUG), Near-Infrared Fluorescence Imaging (PROCEDURE), Pharmacokinetic Study (OTHER).

Who is sponsoring clinical trial NCT03582124?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03582124 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Lung Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Lung Cancer AJCC v8

All registered trials for this condition

Lung Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.